Literature DB >> 16331247

Absence of PIK3CA hotspot mutations in hepatocellular carcinoma in Japanese patients.

Y Tanaka1, F Kanai, M Tada, Y Asaoka, B Guleng, A Jazag, M Ohta, T Ikenoue, K Tateishi, S Obi, T Kawabe, O Yokosuka, M Omata.   

Abstract

A recent study revealed that the p110alpha (PIK3CA), catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is somatically mutated in many types of cancer. For example, PIK3CA is mutated in an estimated 35.6% of hepatocellular carcinoma (HCC) cases. To measure the frequency of PIK3CA hotspot mutations in Japanese HCC patients, exons 9 and 20 of the PIK3CA gene were sequenced in 47 clinical HCC samples. Contrary to expectations, no hotspot mutations were found any of the HCC samples. In addition, we found abnormally migrating waves near the end of exon 9 in the PCR chromatograms from 13 of the 47 samples. PCR amplification and subsequent cloning and sequencing revealed that these chromatograms contained two distinct sequences, the wild-type p110alpha sequence and a different sequence found on human chromosome 22q11.2, the Cat Eye Syndrome region, which contains a putative pseudogene of PIK3CA. These abnormally migrating waves were also found in noncancerous liver tissue, indicating that this was not a result of HCC-associated mutations. Therefore, it is likely that the percentage of hotspot mutations in the PIK3CA gene of Japanese HCC patients is lower than was previously reported.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331247     DOI: 10.1038/sj.onc.1209311

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

Review 1.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Todd Waldman
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 2.  Systems Challenges of Hepatic Carcinomas: A Review.

Authors:  Dhatri Madduru; Johny Ijaq; Sujata Dhar; Saumyadip Sarkar; Naresh Poondla; Partha S Das; Silvia Vasquez; Prashanth Suravajhala
Journal:  J Clin Exp Hepatol       Date:  2018-05-17

3.  Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population.

Authors:  Xun Li; Quanbao Zhang; Wenting He; Wenbo Meng; Jun Yan; Lei Zhang; Xiaoliang Zhu; Tao Liu; Yumin Li; Zhongtian Bai
Journal:  Pathol Oncol Res       Date:  2011-06-12       Impact factor: 3.201

4.  Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors.

Authors:  Brian K Mannakee; Uthra Balaji; Agnieszka K Witkiewicz; Ryan N Gutenkunst; Erik S Knudsen
Journal:  Bioinformatics       Date:  2018-05-15       Impact factor: 6.937

5.  Different subtypes of intraductal papillary mucinous neoplasm in the pancreas have distinct pathways to pancreatic cancer progression.

Authors:  Dai Mohri; Yoshinari Asaoka; Hideaki Ijichi; Koji Miyabayashi; Yotaro Kudo; Motoko Seto; Miki Ohta; Motohisa Tada; Yasuo Tanaka; Tsuneo Ikenoue; Keisuke Tateishi; Hiroyuki Isayama; Fumihiko Kanai; Noriyoshi Fukushima; Minoru Tada; Takao Kawabe; Masao Omata; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2011-11-01       Impact factor: 7.527

6.  Adenoviral gene therapy in hepatocellular carcinoma: a review.

Authors:  Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda
Journal:  Hepatol Int       Date:  2012-04-25       Impact factor: 6.047

7.  Pivotal role of mTOR signaling in hepatocellular carcinoma.

Authors:  Augusto Villanueva; Derek Y Chiang; Pippa Newell; Judit Peix; Swan Thung; Clara Alsinet; Victoria Tovar; Sasan Roayaie; Beatriz Minguez; Manel Sole; Carlo Battiston; Stijn Van Laarhoven; Maria I Fiel; Analisa Di Feo; Yujin Hoshida; Steven Yea; Sara Toffanin; Alex Ramos; John A Martignetti; Vincenzo Mazzaferro; Jordi Bruix; Samuel Waxman; Myron Schwartz; Matthew Meyerson; Scott L Friedman; Josep M Llovet
Journal:  Gastroenterology       Date:  2008-08-20       Impact factor: 22.682

8.  PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.

Authors:  Wei-feng Wang; Yan Xie; Zhi-hua Zhou; Zheng-hong Qin; Jun-chao Wu; Jing-kang He
Journal:  Acta Pharmacol Sin       Date:  2013-11-18       Impact factor: 6.150

9.  Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.

Authors:  Nicole Grabinski; Florian Ewald; Bianca T Hofmann; Katharina Staufer; Udo Schumacher; Björn Nashan; Manfred Jücker
Journal:  Mol Cancer       Date:  2012-11-20       Impact factor: 27.401

10.  PIK3CA mutations in hepatocellular carcinoma in Korea.

Authors:  Heesue Kim; Cheol-Keun Park; Su Jin Lee; Sun Young Rha; Kyu Hyun Park; Ho Yeong Lim
Journal:  Yonsei Med J       Date:  2013-07       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.